ReviewJournal of neuro-oncology2023
Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.
Review in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The prognostic significance of TSPO-PET imaging in IDH-mutant glioma: a single-center, retrospective study.European journal of nuclear medicine and molecular imaging · 2026Article
- Characteristics of [European journal of nuclear medicine and molecular imaging · 2026Article
- Development and First-in-Human Translation of Hyperpolarized [1-Sensors (Basel, Switzerland) · 2026Article
- [Journal of neuro-oncology · 2026Article
- Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.Journal of neuro-oncology · 2025Article
- PET imaging of gliomas: Status quo and quo vadis?Neuro-oncology · 2024Review
- IDH inhibition in gliomas: from preclinical models to clinical trials.Nature reviews. Neurology · 2024Review
- A bis-boron boramino acid PET tracer for brain tumor diagnosis.European journal of nuclear medicine and molecular imaging · 2024Article
- Radiosynthesis and biological evaluation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [Journal of neuro-oncology · 2023Article
- Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.Journal of neuro-oncology · 2023Article
- Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.Molecules (Basel, Switzerland) · 2023Review
- Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A considerable fraction of these tumors typically show no contrast enhancement on MRI, especially when classified as grade 2 according to the World Health Organization classification of Central Nervous System tumors. Major diagnostic challenges in this situation are differential diagnosis, target definition for diagnostic biopsies, delineation of glioma extent for treatment planning, differentiation of treatment-related changes from tumor progression, and the evaluation of response to alkylating agents. The main focus of this review is the role of amino acid PET in this setting. Furthermore, in light of clinical trials using IDH inhibitors targeting the mutated IDH enzyme for treating patients with IDH-mutant gliomas, we also aim to give an outlook on PET probes specifically targeting the IDH mutation, which appear potentially helpful for response assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.